MissionIR Articles

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update regarding its clinical development programs, manufacturing and strategy for bringing its Oncoprex(TM) immunogene therapy to market. A corporate presentation is available on GNPX’s…

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference. ReedSmith is hosting the event,…

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its recent achievements as part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex(TM) immunogene therapy,…

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA per the manufacturing agreement between the…

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced it has initiated the first phase of branding its lead drug candidate, Oncoprex(TM) immunogene therapy, and has completed and submitted non-proprietary drug name selections to…

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning provided an update on the development of its lead drug candidate, Oncoprex(TM) immunogene therapy, in combination with immunotherapy for the treatment of non-small cell lung…

Genprex (NASDAQ: GNPX), a clinical-stage, gene-therapy company, recently announced that it has retained pharmaceutical branding agency Addison Whitney to assist with the naming of the company’s leading drug candidate (http://ibn.fm/ci3KJ). An article further discussing the…

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is developing Oncoprex immunogene therapy as an innovative, gene therapy-based approach for the treatment of non-small cell lung cancer (“NSCLC”). An article further discussing the company reads, “NSCLC is…

Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene-therapy company, this morning announced that it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31,…

Genprex (NASDAQ: GNPX) is a clinical-stage, gene-therapy company focused on the advancement of its lead drug candidate, Oncoprex(TM) immunogene therapy. Oncoprex is an investigational therapy for non-small cell lung cancer (“NSCLC”). An article discussing the…

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) this morning announced that it has retained the services of leading pharmaceutical branding agency, Addison Whitney, representing the next step toward commercialization of its lead drug candidate. Utilizing its…

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) recently reported that positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody was recorded by its University of Texas MD Anderson Cancer Center collaborators…

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is focused on the development of potentially life-changing technologies for cancer patients. A recent article discussing GNPX reads, “Genprex holds a portfolio of 30 issued and two pending patents…

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning announced that its collaborators from the University of Texas MD Anderson Cancer Center (“MD Anderson”) detailed positive preclinical data, in a poster presented at the…

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Monday provided a clinical, corporate and financial update for the year ended December 31, 2018. Among other highlights, Genprex reached various milestones in 2018 and early 2019…

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will be presenting at the upcoming ARM Cell & Gene Therapy Investor Day, hosted by the Alliance for Regenerative Medicine, to be held…